These compounds can indirectly diminish production of cholera toxin and other major virulence required by the cholera bacterium to cause disease.

Disclosed herein is a compound engineered by conjugating a cholera toxin (or subunit thereof), to a targeting molecule that assists in targeting the cholera toxin to a specific g-protein coupled receptor on neurons.

It is possible thereby to selectively elute the B subunit for cholera toxin from the matrix.

The anti-toxin intestinal antibodies prevent the cholera toxin from binding to the intestinal mucosal surface thereby preventing the toxin-mediated diarrhoeal symptoms.

In another embodiment of the present invention, the recombinant plasmid contains a salivary binding protein-cholera toxin g(D)A 1 chimeric protein expressed in Salmo nella typhimurium.

Since the early 1990’s, a variant strain of El Tor producing the classical cholera toxin has been circulating.

The present invention provides chimeric proteins such as Salivary Binding Protein (SBR) coupled to the B subunit of cholera toxin.

In “exchange,” the vibrio acquires the ability to produce the cholera toxin, which is encoded in the genome of the bacteriophage.

In “exchange,” the vibrio acquires the ability to produce the cholera toxin, which is encoded in the genome of the bacteriophage.

The non-viral delivery complexes provided by the invention comprise cholera toxin B subunit or functional equivalents thereof and preferably cyclodextrin.

It decreases the intestinal hypersecretion of water and electrolytes induced by cholera toxin or inflammation and does not have effects on basal secretory activity.

The vaccine contains killed whole V. cholerae O1 bacteria and the recombinant non-toxic B-subunit of the cholera toxin (CTB).

In order to become pathogenic, the vibrio must acquire the ability to produce the cholera toxin, which causes the lethal diarrhea of cholera.

Dukoral contains small amounts of inactivated (killed) cholera bacteria and a part of the cholera toxin called the ‘B subunit’.

Disclosed are novel saccharide derivatives which inhibit binding of toxins, such as heat-labile enterotoxin or cholera toxin, to their receptors either in vitro or in vivo.

Toxins such as cholera toxin may increase the secretion or decrease the intake of water and electrolytes, leading to possibly severe dehydration and electrolyte imbalance.[2]

The invention relates to a method of purifying cholera toxin or the enterotoxin of E. coli using a matrix with at least on e ion chosen from among matrix with Ni?+2, Co+2, Cd2 or Zn+2¿ immobilized thereon.

The anti-toxin intestinal antibodies prevent the cholera toxin from binding to the intestinal mucosal surface thereby preventing the toxin-mediated diarrhoeal symptoms.

A monovalent O1 vaccine, composed of killed whole cells of V. cholerae O1 in combination with a recombinant B-subunit of cholera toxin (WC/rBS, Dukoral®).

Two bivalent O1 and O139 vaccines, prepared from killed whole cells and made by different manufacturers, which do not contain cholera toxin B-subunit.

Demonstration of cholera-enterotoxin or the cholera-enterotoxin gene in the isolate

Demonstration of cholera-enterotoxin or the cholera-enterotoxin gene in the isolate